Announcements Trials
Browse Landscape

Status

Completed 5Not yet recruiting 1

Sponsor Class

INDUSTRY 6OTHER 4

Study Type

Interventional 61Observational 6

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 2Leukemia, Myeloid, Chronic-Phase 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Dasatinib × Clear all
NCT07091019 2025-07-29

ASC4REAL-2

Novartis

Not yet recruiting
1,000 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT05286528 2023-10-27

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Pfizer

Completed
1,484 enrolled 6 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02389972 2017-09-11

Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Bristol-Myers Squibb

Completed
128 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02546791 2017-07-26

PASS

Bristol-Myers Squibb

Completed
101 enrolled
Other hematologic neoplasm

Leukemia

NCT01188278 2016-09-30

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Bristol-Myers Squibb

Completed
173 enrolled
Other hematologic neoplasm

Leukemia

NCT02733445 2016-04-11

Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

Bristol-Myers Squibb

Completed
2,650 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡